Methotrexate News and Research RSS Feed - Methotrexate News and Research

Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology. [More]
AESKU.DIAGNOSTICS offers new early prognostic marker for RA

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

Activity and outcome scores like DAS, DAS28, SDAI or CDAI, Larsen Score, etc. are commonly used but are time consuming and not practical in the early phase of rheumatoid arthritis (RA). [More]
Common arthritis drug could help to treat patients with blood cancers

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers. [More]
Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third. [More]
Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

The results of the tREACH trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that initial therapy with combination DMARDs significantly improves measures of disease activity and functional ability in patients with early rheumatoid arthritis (RA). [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Global RA treatment market expected to increase just over $19 billion by 2020

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%. [More]
Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology. [More]
Novel drug target identified for treating rheumatoid arthritis

Novel drug target identified for treating rheumatoid arthritis

Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Study: Rheumatoid arthritis nearly doubles risk of surprise heart attack

Study: Rheumatoid arthritis nearly doubles risk of surprise heart attack

Patients with rheumatoid arthritis are at increased risk of a surprise heart attack, according to new research presented today at ICNC 12 by Dr Adriana Puente, a cardiologist in the National Medical Centre "20 de Noviembre" ISSSTE in Mexico City, Mexico. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. [More]
BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

BMI plays role in rheumatoid arthritis patients' ability to achieve sustained remission

A study by Hospital for Special Surgery researchers finds that body mass index (BMI) plays a role in rheumatoid arthritis (RA) patients' ability to achieve a sustained remission. Looking at patients who had received an RA diagnosis within the past 12 months, investigators found that those who were significantly underweight or overweight/obese were the least likely to remain in remission. [More]
Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience to present new data on Vectra DA at ACR Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that new data on Vectra DA will be featured at the 2014 American College of Rheumatology Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. [More]
New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost. Doctoral researcher Diederik De Cock (KU Leuven) describes the strategy in a new study published in Annals of Rheumatic Diseases. [More]
Advertisement
Advertisement